Search research articles
Contact Us
Filters
Showing results (161-170 of 184) with videos related to
Page
of 19
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 22, 2025
FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma
Sara Taranto, Jessica Faletti, Mariangela Tamburello, et al.
Oncotarget
|
June 1, 2017
U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis
Francesca Caccuri, Roberto Ronca, Andrea S Laimbacher, et al.
Tumori
|
August 19, 2004
45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003
Raffaella Giavazzi, Massimo Aglietta, Annalisa Astolfi, et al.
Cell Death Discovery
|
March 5, 2023
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Federica Maccarinelli, Daniela Coltrini, Silvia Mussi, et al.
Cancer Cell
|
August 13, 2015
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy
Roberto Ronca, Arianna Giacomini, Emanuela Di Salle, et al.
International Journal of Molecular Sciences
|
August 26, 2022
β-Galactosylceramidase Deficiency Causes Upregulation of Long Pentraxin-3 in the Central Nervous System of Krabbe Patients and <i>Twitcher</i> Mice
Daniela Coltrini, Adwaid Manu Krishna Chandran, Mirella Belleri, et al.
The Journal of Biological Chemistry
|
January 9, 2010
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds
Giorgio Colombo, Barbara Margosio, Laura Ragona, et al.
Oncotarget
|
April 21, 2017
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Antonio Sacco, Adriano Fenotti, Loredana Affò, et al.
Cancer Research
|
February 8, 2020
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer
Marianna Cerasuolo, Federica Maccarinelli, Daniela Coltrini, et al.
International Immunopharmacology
|
September 6, 2025
A synthetic humanized camelid single-domain antibody targeting VEGF exhibits in vitro antiangiogenic effects
Isabel Gonzalez-Moya, Yasmiana Muñoz, Jahaziel Gasperin-Bulbarela, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 184) with videos related to
Sort By:
Page
of 19
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 22, 2025
FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma
Sara Taranto, Jessica Faletti, Mariangela Tamburello, et al.
Oncotarget
|
June 1, 2017
U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis
Francesca Caccuri, Roberto Ronca, Andrea S Laimbacher, et al.
Tumori
|
August 19, 2004
45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003
Raffaella Giavazzi, Massimo Aglietta, Annalisa Astolfi, et al.
Cell Death Discovery
|
March 5, 2023
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Federica Maccarinelli, Daniela Coltrini, Silvia Mussi, et al.
Cancer Cell
|
August 13, 2015
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy
Roberto Ronca, Arianna Giacomini, Emanuela Di Salle, et al.
International Journal of Molecular Sciences
|
August 26, 2022
β-Galactosylceramidase Deficiency Causes Upregulation of Long Pentraxin-3 in the Central Nervous System of Krabbe Patients and <i>Twitcher</i> Mice
Daniela Coltrini, Adwaid Manu Krishna Chandran, Mirella Belleri, et al.
The Journal of Biological Chemistry
|
January 9, 2010
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds
Giorgio Colombo, Barbara Margosio, Laura Ragona, et al.
Oncotarget
|
April 21, 2017
The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions
Antonio Sacco, Adriano Fenotti, Loredana Affò, et al.
Cancer Research
|
February 8, 2020
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer
Marianna Cerasuolo, Federica Maccarinelli, Daniela Coltrini, et al.
International Immunopharmacology
|
September 6, 2025
A synthetic humanized camelid single-domain antibody targeting VEGF exhibits in vitro antiangiogenic effects
Isabel Gonzalez-Moya, Yasmiana Muñoz, Jahaziel Gasperin-Bulbarela, et al.
Page
of 19